BLU.TO
Price:
$19.48
Market Cap:
$1.78B
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.[Read more]
Industry
Biotechnology
IPO Date
2000-06-22
Stock Exchange
TSX
Ticker
BLU.TO
According to BELLUS Health Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -20.29. This represents a change of 68.40% compared to the average of -12.05 of the last 4 quarters.
The mean historical PE Ratio of BELLUS Health Inc. over the last ten years is 20.30. The current -20.29 PE Ratio has changed -10096.95% with respect to the historical average. Over the past ten years (40 quarters), BLU.TO's PE Ratio was at its highest in in the June 2017 quarter at 36.74. The PE Ratio was at its lowest in in the March 2015 quarter at -344.08.
Average
20.30
Median
-11.48
Minimum
-40.03
Maximum
339.79
Discovering the peaks and valleys of BELLUS Health Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.29%
Maximum Annual PE Ratio = 339.79
Minimum Annual Increase = -Infinity%
Minimum Annual PE Ratio = -40.03
Year | PE Ratio | Change |
---|---|---|
2022 | -12.40 | 39.50% |
2021 | -8.89 | 59.19% |
2020 | -5.58 | -Infinity% |
2019 | 0 | -100.00% |
2018 | -18.56 | 5.70% |
2017 | -17.56 | 66.09% |
2016 | -10.57 | -103.11% |
2015 | 339.79 | -948.89% |
2014 | -40.03 | 72.32% |
2013 | -23.23 | 2.29% |
The current PE Ratio of BELLUS Health Inc. (BLU.TO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-8.96
5-year avg
-9.09
10-year avg
20.30
BELLUS Health Inc.’s PE Ratio is less than Aptose Biosciences Inc. (-0.16), less than Oncolytics Biotech Inc. (-4.34), less than Theratechnologies Inc. (-19.86), greater than Knight Therapeutics Inc. (-26.97), less than IMV Inc. (-0.18),
Company | PE Ratio | Market cap |
---|---|---|
-0.16 | $9.96M | |
-4.34 | $123.18M | |
-19.86 | $77.25M | |
-26.97 | $570.51M | |
-0.18 | $13.12M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BELLUS Health Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BELLUS Health Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is BELLUS Health Inc.'s PE Ratio?
How is the PE Ratio calculated for BELLUS Health Inc. (BLU.TO)?
What is the highest PE Ratio for BELLUS Health Inc. (BLU.TO)?
What is the 3-year average PE Ratio for BELLUS Health Inc. (BLU.TO)?
What is the 5-year average PE Ratio for BELLUS Health Inc. (BLU.TO)?
How does the current PE Ratio for BELLUS Health Inc. (BLU.TO) compare to its historical average?